Medizinische Universität Graz - Research portal
Navigation/Search
- Researchers
- Institutions
- Projects
- Publications
- Partners
- Sponsors
- Equipment
- Knowhow
- Fields of Research
"Faces" of the day:
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Kriegl, L; Hatzl, S; Zurl, C; Reisinger, AC; Schilcher, G; Eller, P; Gringschl, Y; Muhr, T; Meinitzer, A; Prattes, J; Hoenigl, M; Krause, R.
Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation.
J Antimicrob Chemother. 2022; 77(9):2500-2505
Doi: 10.1093/jac/dkac196
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Hatzl Stefan
- Krause Robert
- Kriegl Lisa
- Co-authors Med Uni Graz
- Eller Philipp
- Hönigl Martin
- Meinitzer Andreas
- Prattes Jürgen
- Reisinger Alexander Christian
- Schilcher Gernot
- Zurl Christoph Johann
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Isavuconazole is an antifungal drug used for treatment of invasive fungal infections. Critically ill COVID-19 and influenza patients require extracorporeal membrane oxygenation (ECMO) in cases with severe acute respiratory distress syndrome and have risk factors for invasive pulmonary aspergillosis. Little is known about isavuconazole plasma concentrations during ECMO. OBJECTIVES: To determine isavuconazole plasma concentrations in seven patients treated with intravenous isavuconazole under ECMO and the influence of the ECMO circuit immediately after the first isavuconazole dose. METHODS: Critically ill patients treated with isavuconazole (standard doses) and ECMO were included in this study. Sixty-four blood samples used for measurement of isavuconazole concentrations were collected at several timepoints starting 2 h after the first isavuconazole dose up to 168 h. An additional 27 blood samples were drawn from the inflow and outflow line of the membrane oxygenator to assess any potential isavuconazole clearance effect of the ECMO oxygenation device and the lines. RESULTS: Median isavuconazole trough levels above 1 μg/mL (min. 0.83, max. 1.73) or 2 μg/mL (min. 0.84, max. 2.97) were achieved 24 h or 96 h after the first dose of isavuconazole. The isavuconazole plasma concentrations pre (inflow line) and post (outflow line) the membrane oxygenator were directly correlated (ρ = 0.987, R2 = 0.994, P < 0.001). Post membrane oxygenator isavuconazole concentrations were directly correlated to contemporaneous samples obtained from the arterial lines of patients (ρ = 0.942, R2 = 0.945, P < 0.001). CONCLUSIONS: Isavuconazole concentrations might be influenced by the higher volume of distribution due to ECMO therapy, but were not altered by the ECMO oxygenator and achieved median plasma concentrations >1 μg/mL 24 h after the first loading dose.
- Find related publications in this database (using NLM MeSH Indexing)
- COVID-19 - administration & dosage
- Critical Illness - therapy
- Extracorporeal Membrane Oxygenation - adverse effects
- Humans - administration & dosage
- Nitriles - administration & dosage
- Pyridines - administration & dosage
- Triazoles - therapeutic use